Antiphospholipid antibodies and the antiphospholipid syndrome: clinical significance and treatment

Seminars in Thrombosis and Hemostasis
Ronald A AshersonDoruk Erkan

Abstract

This article provides a review of the various types of antiphospholipid (aPL) antibodies and antiphospholipid syndromes, their prevalence, presumed origin, relationship to autoimmunity in general, and their role in the body's defenses and apoptosis. New hypotheses such as the role of antibodies to beta2 glycoprotein I (beta2GPI) and the signaling of toll-like receptors are also discussed, as is the spectrum of clinical manifestations associated with the demonstration of these antibodies, now assumed to be "pathogenic." A distinction is made between antibodies present in sera of patients with a variety of microangiopathic syndromes (MAPS; e.g., HELLP syndrome, thrombotic thrombocytopenic purpura, and thrombotic microangiopathic syndromes). In these conditions, the antibodies might not be "pathogenic" but, alternatively, generated by small vessel endothelial damage. These conditions are differentially referred to as microangiopathic antiphospholipid-associated syndromes, and they should be differentiated from the microvascular occlusions that are seen in the antiphospholipid syndrome. Current treatments of the antiphospholipid syndrome are briefly reviewed.

Citations

Dec 5, 2008·Clinical Reviews in Allergy & Immunology·Jose A Gómez-PuertaClaudio Galarza-Maldonado
Jan 14, 2011·Clinical Reviews in Allergy & Immunology·Yinon ShapiraNancy Agmon Levin
Nov 5, 2010·Journal of Cardiothoracic Surgery·Ioanna KoniariEfstratios Apostolakis
Feb 1, 2011·Clinical Chemistry and Laboratory Medicine : CCLM·Emmanuel J Favaloro, Richard C W Wong
May 28, 2014·Thrombosis Research·Ilene Ceil Weitz
Feb 20, 2009·European Journal of Haematology·Katrien Devreese, Marc F Hoylaerts
Dec 9, 2008·Pediatric Blood & Cancer·Amulya A Nageswara RaoVilmarie Rodriguez
Jun 26, 2012·Immunological Reviews·Betty Diamond, Bruce T Volpe
Aug 30, 2012·Journal of Medical Virology·M GoeijenbierE C M van Gorp
Jan 7, 2015·The Journal of Emergency Medicine·Lia I LosonczyColin M Feeney
May 1, 2010·Auto- Immunity Highlights·Emmanuel J Favaloro, Richard C W Wong
Jan 19, 2017·Annual Review of Medicine·Ozan Unlu, Doruk Erkan
Sep 26, 2017·Intractable & Rare Diseases Research·Rukma ParthviArunabh Talwar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis